July 24, 2016
Recommended Topic Related To:


"The U.S. Food and Drug Administration will complete its phase-out of all inhaler medical products containing chlorofluorocarbons (CFCs) by Dec. 31, 2013. This effort is to comply with an international treaty to protect the ozone layer by phasing "...




Severe Bronchospasm

Prior to administration patients should be informed of the potential for bronchial challenge testing with ARIDOL (mannitol inhalation powder) to cause severe bronchospasm and of the potential symptoms they may experience.

Subjects with Certain Co-morbid Conditions

Bronchial challenge testing with ARIDOL (mannitol inhalation powder) should be performed with caution in patients having severe cough, ventilatory impairment, spirometry-induced bronchoconstriction, hemoptysis of unknown origin, pneumothorax, recent abdominal or thoracic surgery, recent intraocular surgery, unstable angina, or active upper or lower respiratory tract infection or other conditions that may worsen with the use of a bronchial irritant.

Last reviewed on RxList: 10/29/2010
This monograph has been modified to include the generic and brand name in many instances.

Report Problems to the Food and Drug Administration


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Allergies & Asthma

Improve treatments & prevent attacks.